Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone + Azelastine FDC for Seasonal Allergic Rhinitis
NCT05311475Phase 3Completed
- Sponsor
- Sandoz
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of mometasone furoate + azelastine in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Sandoz. Primary endpoint: Change from baseline in the daily Total Nasal Symptom Score at Day 7. Started Apr 2022; status: completed.
02
Drugs
mometasone furoate + azelastine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05311475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311475.